Newer immunosuppressive drugs: Their potential role in rheumatoid arthritis therapy

Drugs

Volumn 62, Issue 6, 2002, Pages 891-907

  Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ANTIRHEUMATIC AGENT; CHLOROQUINE; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; PHOSPHOTRANSFERASE; RAPAMYCIN; SALAZOSULFAPYRIDINE; SB 242235; SBS 220025; SBS 242235; SYNAPTOPHYSIN; TACROLIMUS; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; CHRONICITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONTROL; HUMAN; INFECTION; INFLAMMATION; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; TISSUE INJURY;

EID: 0036241265     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262060-00003     Document Type: Review

References (97)

1. Mechanisms of disease: Rheumatoid arthritis pathophysiology and implications for therapy
2. The immunopathogenesis of rheumatoid arthritis
3. The immunopathogenesis of rheumatoid arthritis
4. New insights into the pathogenesis and treatment of rheumatoid arthritis
5. Cytokine pathways and joint inflammation in rheumatoid arthritis
6. Transcription factors
7. Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases
8. Signal transduction and transcription factors in rheumatic disease
9. Infliximab (climatic anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase II trial
10. Transcription control by protein phosphorylation: Signal transmission from the cell surface to the nucleus
11. Mitogen-activated protein kinase cascades and the regulation of gene expression
12. Transcription factor interactions: Basics on zippers
13. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
14. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
15. Transcription factor ATF-2 regulation by JNK signal transduction pathway
16. Transcription factor NF-kB: An emerging regulator of inflammation
17. The role of Jun, Fos and AP-1 complex in cell proliferation and transformation
18. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms
19. Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Thr-182 and both residues are phosphorylated in chemically stressed KB cells
20. Intracellular signaling pathways as a target for the treatment of rheumatoid arthritis
21. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin-2 promoter
22. Molecular mechanisms of immunosuppression by cyclosporine, FK-506 and rapamycin
23. Cyclosporine A in rheumatoid arthritis
24. The use of cyclosporine A microemulsion in rheumatoid arthritis: Conclusion of an international review
25. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporine A
26. Radiological evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine
27. A randomized double blind 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis
28. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: Comparison of low-dose cyclosporine and parenteral gold
29. Cyclosporine-A in the treatment of early rheumatoid arthritis. A prospective randomized 24-month study
30. Influence of cyclosporine A on radiological progression in early rheumatoid arthritis patients: A 42-month prospective study
31. Disease modifying anti-rheumatic drugs in early rheumatoid arthritis: A long-term observational study
32. Tacrolimus, a new immunosuppressant - A review of the literature
33. Immunosuppressive effect of FK-506 on collagen-induced arthritis in rats
34. Cyclosporine A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis in mice
35. FK-506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis
36. FK-506, an immunosuppressant partially inhibits interleukin 6 production by adherent rheumatoid synovial cells
37. Tacrolimus (FK-506) in the treatment of severe refractory rheumatoid arthritis: Initial experience in 12 patients
38. Cyclosporine, FK506, rapamycin and other immunomodulators
39. Rapamycin, a potential disease-modifying antiarthritis drug
40. Inhibition of T and B lymphocyte proliferation by rapamycin
41. Inhibition of the immune response by rapamycin, a new antifugal antibiotic
42. Ricerche bacteriologiche e chimiche sulle alterazion del mais
43. Studies in the biochemistry of micro-organisms
44. A new, potent immunosuppressive agent
45. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxy guanosine nucleotide depletion
46. The inhibition of nucleic acid synthesis by mycophenolic acid
47. Metabolism and biochemistry of mycophenolic acid
48. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
49. Mycophenolate mofetil (RS-61443): Preclinical, clinical and three-year experience in heart transplantation
50. Investigational agents for rheumatoid arthritis
51. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
52. Immunologic changes in patients with rheumatoid arthritis treated for one year with a new DMARD, mycophenolate mofetil
53. New DMARD, mycophenate mofetil, effectively treats refractory rheumatoid arthritis patients for one year
54. How does leflunomide modulate the immune response in rheumatoid arthritis?
55. Mechanism of action for leflunomide in rheumatoid arthritis
56. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
57. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
58. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double blind, randomized, multicentre trial
59. Tumor necrosis factor alpha stimulates resoption and inhibits synthesis of proteoglycan and cartilage
60. Transgenic mice expressing human tumor necrosis factor: A predictive model of arthritis
61. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
62. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
63. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
64. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis
65. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
66. Infliximab and methotrexate in the treatment of rheumatoid arthritis
67. Tuberculosis associated with infliximab, a tumor necrosis factor alpha - Neutralizing agent
68. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
69. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
70. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate
71. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
72. Biological basis for interleukin-1 in disease
73. Arterial inflammatory in mice lacking the interleukin 1 receptor antagonist gene
74. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
75. The effects of interleukin-1 receptor antagonist on oxidant-induced arthritis in mice
76. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis
77. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
78. IL-1 and TNF-induced bone resorption in mediated by p38 mitogen activated protein kinase
79. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α or IL-1β-stimulated rheumatoid synovial fibroblast
80. Jun N-terminal kinase in rheumatoid arthritis
81. Activation, differential, localization and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, C-Jun N-Terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis
82. Potent inhibitors of the MAP kinase p38
83. p38 mitogen-activated kinase inhibitors mechanisms and therapeutic potentials
84. Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: Inhibition of tumor necrosis factor as a possible mechanism of action
85. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
86. SB203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
87. Pyridinylimidazole compound SB203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase
88. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB203580 and PD98059
89. SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
90. The structural basis for the specificity of pyridinylamidazole inhibitors of p38 MAP kinase
91. Highly specific inhibitor of p38 MAP kinase binds in the ATP pocket
92. Pharmacological effects of SB220025 a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
93. Disease-modifying activity of SB242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
94. The discovery of RPR200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy
95. New inhibitors of p38 kinase
96. Discovery of a new class of p38 kinase inhibitors
97. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, Furyl and Pyrroly Ureas